文献速递神经肿瘤

立体定向放射外科治疗非典型与间变性脑膜瘤:国际多中心队列结果

Stereotactic Radiosurgery for Atypical (World Health Organization II) and Anaplastic (World Health Organization III) Meningiomas: Results From a Multicenter, International Cohort Study.
PubMed 文献 · Neurosurgery · 2021-01-01

该国际多中心回顾性队列纳入271例接受立体定向放射外科(SRS)治疗的非典型(233例,85.9%)或间变性(38例,14.0%)脑膜瘤患者,多数为单次SRS(97.4%),平均靶剂量14.8 Gy。5年无进展生存率与总生存率分别为33.6%和77.0%,年龄增长与Ki-67>15%与PFS负相关,间变性脑膜瘤、年龄增长及KPS降低与OS缩短相关。

要点

  • 非典型/间变性脑膜瘤SRS后5年PFS仅33.6%,需认识其短期控制、长期复发特点
  • Ki-67>15%与PFS负相关(HR=1.66,P<.03),提示增殖指数高者复发风险增加
  • 辅助与挽救性SRS对PFS/OS无差异,间变性脑膜瘤OS更差(HR=3.21,P<.05)

核心结论

  • 非典型与间变性脑膜瘤仍是治疗困难的肿瘤,SRS可短期控制但5年PFS率低,需改进治疗选择。

研究设计与样本

  • 国际多中心回顾性队列研究,共271例接受SRS的非典型(n=233,85.9%)或间变性(n=38,14.0%)脑膜瘤患者。
  • 单次SRS最常见(n=264,97.4%),平均靶剂量14.8 Gy;SRS作为辅助治疗85例(31.4%)、挽救治疗182例(67.2%)、初治1.5%。
  • 肿瘤进展采用RANO标准评估,PFS/OS相关因素用Kaplan-Meier分析与Cox比例风险模型评估。

主要发现

  • 5年PFS率为33.6%,5年OS率为77.0%。
  • 年龄增长(HR=1.01,P<.05)与Ki-67指数>15%(HR=1.66,P<.03)与PFS负相关。
  • 间变性脑膜瘤(HR=3.21,P<.05)、年龄增长(HR=1.04,P=.04)及KPS降低(HR=0.95,P=.04)与OS缩短相关。
  • 辅助与挽救性SRS对PFS/OS无影响;亚组分析中手术至SRS间隔缩短改善非典型脑膜瘤PFS(HR=0.99,P=.02)。
  • 放射性坏死发生34例(12.5%);5年再次手术与再次放疗率分别为33.8%和60.4%。

关键数值与推荐

  • 5年PFS率33.6%、5年OS率77.0%(271例AM/MM患者SRS后)。
  • Ki-67>15%者PFS风险比HR=1.66(P<.03);间变性脑膜瘤OS风险比HR=3.21(P<.05)。
  • KPS每降低与OS风险比HR=0.95(P=.04);年龄与OS风险比HR=1.04(P=.04)。

临床怎么用

  • 对非典型/间变性脑膜瘤可采用SRS进行短期控制,但应预期5年PFS率偏低并加强随访。
  • Ki-67>15%或间变性病理提示复发/生存风险更高,可据此强化个体化随访与多学科决策。
  • 辅助与挽救性SRS未见PFS/OS差异,选择时机需结合手术至SRS间隔等因素综合判断。

局限性

  • 为回顾性多中心队列研究,原文未报告各中心治疗选择与随访差异等潜在偏倚信息。
  • 原文未报告SRS剂量处方的统一方案及放疗坏死相关危险因素分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atypical and anaplastic meningiomas have reduced progression-free/overall survival (PFS/OS) compared to benign meningiomas. Stereotactic radiosurgery (SRS) for atypical meningiomas (AMs) and anaplastic meningiomas (malignant meningiomas, MMs) has not been adequately described. OBJECTIVE: To define clinical/radiographic outcomes for patients undergoing SRS for AM/MMs. METHODS: An international, multicenter, retrospective cohort study was performed to define clinical/imaging outcomes for patients receiving SRS for AM/MMs. Tumor progression was assessed with response assessment in neuro-oncology (RANO) criteria. Factors associated with PFS/OS were assessed using Kaplan-Meier analysis and a Cox proportional hazards model. RESULTS: A total of 271 patients received SRS for AMs (n = 233, 85.9%) or MMs (n = 38, 14.0%). Single-fraction SRS was most commonly employed (n = 264, 97.4%) with a mean target dose of 14.8 Gy. SRS was used as adjuvant treatment (n = 85, 31.4%), salvage therapy (n = 182, 67.2%), or primary therapy (1.5%). The 5-yr PFS/OS rate was 33.6% and 77.0%, respectively. Increasing age (hazard ratio (HR) = 1.01, P < .05) and a Ki-67 index > 15% (HR = 1.66, P < .03) negatively correlated with PFS. MMs (HR = 3.21, P < .05), increased age (HR = 1.04, P = .04), and reduced KPS (HR = 0.95, P = .04) were associated with shortened OS. Adjuvant versus salvage SRS did not impact PFS/OS. A shortened interval between surgery and SRS improved PFS for AMs (HR = 0.99, P = .02) on subgroup analysis. Radiation necrosis occurred in 34 (12.5%) patients. Five-year rates of repeat surgery/radiation were 33.8% and 60.4%, respectively. CONCLUSION: AM/MMs remain challenging tumors to treat. Elevated proliferative indices are associated with tumor recurrence, while MMs have worse survival. SRS can control AM/MMs in the short term, but the 5-yr PFS rates are low, underscoring the need for improved treatment options for these patients.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Shepard MJ, Xu Z, Kearns K, et al. Stereotactic Radiosurgery for Atypical (World Health Organization II) and Anaplastic (World Health Organization III) Meningiomas: Results From a Multicenter, International Cohort Study. Neurosurgery. 2021. PMID: 33469655. doi:10.1093/neuros/nyaa553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。